Published in Medical Verdicts and Law Weekly, March 15th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at FermaVir Pharmaceuticals.
Report 1: FermaVir Pharmaceuticals, Inc. (FMVR) announced the closing of a private placement totaling $1.27 million.
"The proceeds from this financing will allow FermaVir to fund the remaining preclinical work to complete and file an Investigational New Drug Application (INDA) with the U.S. FDA on its FV-100 for shingles," said Geoffrey Henson, CEO of FermaVir. FV-100 is a powerful specific inhibitor of varicella zoster virus, the cause...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Verdicts and Law Weekly